Glenmark Pharmaceuticals acquires and launches acetylcysteine injection

Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA

Senores Pharmaceuticals begins operations at greenfield API facility

This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.

Glenmark Pharmaceuticals USA launches Epinephrine Injection USP

This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.

Cadila Pharmaceuticals opens advanced pharmaceutical warehouse

Somaiya Vidyavihar University hosts conference on ‘Clinical Translation of Biomaterials for Future Healthcare’

Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business

The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market

KIMS enters into agreement to manage Splendid Hospitals, Hyderabad

Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals

Senores Pharmaceuticals acquires ANDA for Roflumilast 250 mcg and 500 mcg tablets

Glenmark Pharmaceuticals USA launches Clindamycin Phosphate Foam, 1%

Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.

IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr

Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24